Novavax makes a management promotion

Jody Lichaa moves up to Vice President, Quality Assurance

Novavax, a developer of recombinant nanoparticle vaccines and adjuvants, has named Jody Lichaa as Vice President, Quality Assurance.

Lichaa joined Novavax as Executive Director, Quality Assurance in October 2011. She is responsible for providing strategy, oversight, and direction of the company’s quality assurance.

Prior to joining Novavax, she was Senior Director, Quality at PharmAthene from 2005 until 2011, where she managed global QA/QC activities. Her prior experience includes quality assurance positions of increasing responsibility in a number of companies including Baxter, Shire and BioReliance.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Pharmaceutical

Zika outbreak gives rise to global fears

Zika may not be a new virus but its newly confirmed ability to cause foetal brain abnormalities makes the search for a treatment or a vaccine a high priority. Dr Sarah Houlton looks at the latest initiatives
Research & Development

Novavax vaccine candidate produces immune response against deadly virus

Study by University of Maryland School of Medicine highlights potential effective means for preventing MERS-CoV
Research & Development

Novavax, CPL Biologicals and ICGEB to develop malaria vaccine

Will combine Novavax VLP vaccine technology with CPLB manufacturing and ICGEB research capabilities
Manufacturing

Novavax signs long-term lease on vaccine plant

Will relocate corporate hq to same campus in Gaithersburg
Research & Development

US HHS awards influenza contracts worth US$215m

Novavax and VaxInnate to develop VLP and recombinant influenza vaccines, respectively
Regulatory

FDA clears Novavax RSV vaccine candidate for early stage trial

Novavax resolves question about chemistry, manufacturing and controls
Research & Development

Novavax RSV vaccine ‘safe and well tolerated’

Firm ready to advance towards human clinical trials
Subscribe now